We monitor your progress and make adjustments as needed
in diet-induced obese mice, 5-Amino-1-MQ significantly reduces total body weight, fat mass, and adipocyte size, while improving insulin sensitivity and glucose tolerance 2,3
Blocking NNMT is expected to raise SAM availability, but SAM participates in many cellular processes, so research must establish that selectively raising it does not perturb other methylation pathways
AOD 9604 differs from both CJC-1295 and tesamorelin in that it does not act on the growth hormone-releasing hormone receptor or stimulate endogenous GH secretion
What the Research Says About Safety Clinical studies on AOD9604 indicate that the peptide is generally welltolerated: In human trials, no significant adverse effects were reported at doses up to 1 mg/day (safety summary) Unlike growth hormone therapies, AOD9604 does not meaningfully elevate IGF1 levels (human data), which may reduce the risk of unwanted growthrelated side effects